At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Ritlecitinib +1 moredrug
Likely dose
Ritlecitinib 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD STUDY TO ESTIMATE THE EFFECT OF MULTIPLE-DOSE RITLECITINIB (PF-06651600) ON THE PHARMACOKINETICS OF SINGLE-DOSE TOLBUTAMIDE IN HEALTHY PARTICIPANTS
In Brief
A Phase 1 clinical trial evaluating Ritlecitinib and Tolbutamide for Healthy Volunteers. Completed, enrolled 12 participants across 1 site.
Detailed Summary
This is a Phase 1, 2-period, multiple-dose, open-label, single fixed sequence study of the effect of ritlecitinib on tolbutamide pharmacokinetics in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartNov 2021
Primary CompletionJan 2022
TodayJul 2026
First PostedOct 28, 2021
Enrollment StartNov 2, 2021
Primary CompletionJan 10, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.7 years ago
Interventions
Ritlecitinibdrug
Ritlecitinib 200 mg provided as four 50 mg oral capsules
Tolbutamidedrug
Tolbutamide 500 mg provided as one 500 mg oral tablet